Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab

BACKGROUND: In the FIRE-3 trial, overall survival (OS) was significantly longer in patients treated with FOLFIRI plus cetuximab (C-mab) than in those treated with FOLFIRI plus bevacizumab (Bev), but progression-free survival (PFS) was not significantly different. This may be associated with the deep...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Onco Targets Ther
Главные авторы: Osumi, Hiroki, Matsusaka, Satoshi, Suenaga, Mitsukuni, Shinozaki, Eiji, Mizunuma, Nobuyuki
Формат: Artigo
Язык:Inglês
Опубликовано: Dove Medical Press 2015
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4532210/
https://ncbi.nlm.nih.gov/pubmed/26273206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S87101
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы